Innovative therapeutics

About us

Leadership Team

Management Team

Under the leadership of Chairman and Chief Executive Officer, Mr. Jean-Jacques Bienaimé, BioMarin’s executive management team includes accomplished leaders with deep and broad executive experience. Supported by a staff of approximately 2,200 employees worldwide, BioMarin is focused on delivering first-in-class and best-in-class therapeutics to patients with rare genetic diseases.

Jean-Jacques Bienaimé
Chairman and Chief Executive Officer
Philip Lo Scalzo
Senior Vice President,
Chief Compliance Officer
Robert A. Baffi, Ph.D.
President of Global Manufacturing and Technical Operations
G. Eric Davis
Executive Vice President,
General Counsel and Secretary
Henry J. Fuchs, M.D.
President, Worldwide Research & Development
Amy Wireman
Group Vice President, Human Resources
Dan Spiegelman
Executive Vice President
and Chief Financial Officer
Jeff Ajer
Executive Vice President and Chief Commercial Officer
Dr. Brinda Balakrishnan, M.D., Ph.D.
Group Vice President, Corporate and Business Development
Lon Cardon, Ph.D.
Chief Scientific Strategy Officer

 

Board of Directors

Jean-Jacques Bienaimé
Chairman and Chief Executive Officer
Elizabeth McKee Anderson5
Director, Insmed, Inc.
Former Worldwide Vice President, Infectious Diseases and Vaccines at Janssen Pharmaceuticals, Inc
Willard H. Dere, M.D. 7,8
Professor of Internal Medicine; B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research
Executive Director of Personalized Health
Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center
Michael Grey 2,8
President and Chief Executive Officer, Amplyx Pharmaceuticals, Inc.
Chairman and Chief Executive Officer, Reneo Pharmaceuticals, Inc.
Venture Partner, Pappas Ventures
Elaine Heron 3,5,8
Former Biotech Executive
Robert Hombach 1,6
Former Chief Financial Officer and Chief Operations Officer, Baxalta
V. Bryan Lawlis5,8
President and Chief Executive Officer,
Itero Biopharmaceuticals, Inc.
Alan Lewis, Ph.D.4,6
President, CEO and Board Member
DiaVacs
Randy Meier
Lead Independent DirectorPresident – International, EVP and Chief Financial Officer of Owens & Minor, Inc.
David Pyott3,6,7
Former Chairman and CEO,
Allergan
Dennis J. Slamon, M.D., Ph.D.,7,8
Professor of Medicine
Director, Clinical/Translational Research, Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women’s Cancer Research Program
David Geffen School of Medicine at UCLA
1Chairman, Audit Committee
2 Chairman, Compensation Committee
3 Chairman, Corporate Governance and Nominating Committee
4 Chairman, Science and Technology Committee
5 Member, Audit Committee
6 Member, Compensation Committee
7 Member, Corporate Governance and Nominating Committee
8 Member, Science and Technology Committee

BioMarin’s management team represents a dynamic cross-section of business, clinical and biotechnical expertise; strong leaders with a proven track record of providing rapid access to breakthrough therapeutics.

LEARN MORE

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

PALYNZIQ®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information

Top